quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 28, 2025

GE HealthCare CEO Peter Arduini is forging a new chapter for the $20 billion-a-year business while drawing on Jack Welch’s legacy

View original at finance.yahoo.com
GE HealthCare CEO Peter Arduini is forging a new chapter for the $20 billion-a-year business while drawing on Jack Welch’s legacy On Jan. 4, 2023, GE HealthCare Technologies (No…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • R&D investment doubled from $750-800 million in 2018 to over $1.4 billion currently

    80% confidence
  • GE HealthCare stock is up almost 50% since IPO on January 4, 2023

    80% confidence
  • Authenticity and direct communication are critical for CEOs in today's world with younger employee base and social media

    80% confidence
  • GE gave employees bold assignments at a very young age and had a tough but fair culture under Jack Welch

    80% confidence
  • Innovation requires a 3 to 5 year cycle in the medical technology business

    80% confidence
  • Med tech is an American gem with 70%+ of products made in the United States and majority of IP originating there

    80% confidence
  • Larry Culp characterized himself as a down-to-earth, focused, and intentional leader

    80% confidence
  • GE HealthCare reduced China imports from 75% to now making 85-90% of products locally for the China market

    80% confidence
  • China will eventually become the largest healthcare market with 1.4 billion people

    80% confidence
  • Harmony between China and the U.S. is beneficial for the world and necessary for GE HealthCare to reach full potential

    80% confidence
  • As a standalone company, GE HealthCare can make decisions faster with better focus and less noise

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com